{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-23-000657","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.222649+00:00","generated_at":"2026-06-15T00:43:32.777868+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Vivani Medical Q1 net loss $6.3M; maintains IND filing timeline for NPM-119","bullets":["Cash $38.1M at March 31, 2023, down from $45.1M; sufficient to fund operations into H2 2024.","R&D expense $4.0M (+48% YoY); operating expenses $6.6M (+69% YoY) driven by Second Sight acquisition costs.","Net loss $6.3M vs $3.9M in Q1 2022; increase due to $2.7M higher operating expenses.","Plans to file NPM-119 IND with FDA by mid-2023; if cleared, initiate LIBERATE-1 trial in Q3 2023 with top-line data in H1 2024.","Expects to complete Cortigent IPO in Q3 2023; Vivani to retain control after offering."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-23-000657","json":"https://secwatch.observer/filing/0001753926-23-000657.json","markdown":"https://secwatch.observer/filing/0001753926-23-000657.md","text":"https://secwatch.observer/filing/0001753926-23-000657.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392623000657/0001753926-23-000657-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392623000657/g083544_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T00:43:32.777868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8f1f7d72974bdea940ac1f3ea22525c9291cab2d","claim":"Vivani Medical, Inc. reported first quarter ended March 31, 2023 results: net income $6.3 million.","evidence_excerpt":"Net Loss: The net loss was $6.3 million as compared to $3.9 million for the three-months ended March 31, 2023, and 2022, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1266806/000175392623000657/0001753926-23-000657-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"$6.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}